Skip to content
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started
icon
icon

icon
icon
icon Medical trials / View details
cancle-icon

2 Ablative RadioTherapy Treatments for Prostate Cancer (EARTH)

Contact information

icon Merrylee McGuffin, MSc

icon Sunnybrook Health Sciences Centre

icon Toronto, Ontario, Canada, M4N 3M5

Basic information

icon

icon Age

icon 30 Enrollment

icon
Cancer Prostate Cancer
Trial Details
Brief Summary

Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects, less cost and improved system capacity without sacrificing excellent cancer control rates. By the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be superior to standard external beam radiation. While two HDR fractions appear to optimize patient convenience and outcomes while minimizing costs, we wanted to determine the tolerability of combining one MR-guided HDR treatment with one SABR treatment to further reduce HDR resource use while maintaining favourable treatment outcomes.

Official Title

Electively Combining Two Ablative RadioTherapy Treatments for Favorable Risk Prostate Cancer Patients (EARTH)

Selection Criteria
Eligibility Inclusion Criteria
    - Histologically confirmed diagnosis of adenocarcinoma of the prostate

    Favorable risk disease defined as either:
    - Low risk disease: T1-T2c, grade group 1, PSA < 10 ng/ml or
    - Favorable intermediate risk disease: One of T2c, grade group 2, or PSA 10-20 ng/ml. Patients cannot have percent core positivity > 50%
    - Prostate volume < 60 cc as determined by US, CT or MRI
    - Ability to undergo MR imaging
    - Provide written informed consent
Eligibility Exclusion Criteria
    - Documented nodal or distant metastases
    - Previous pelvic radiotherapy
    - Previous transurethral resection of prostate, previous prostatectomy or HIFU
    - Use of androgen deprivation therapy. Use of 5-alpha-reductase inhibitors permitted
    - Poor baseline urinary function defined as International - - Prostate Symptom Score (IPSS) >15
    - Contra-indication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
    - Significant medical co-morbidity rendering patient unsuitable for general anaesthesia

Join us! Be part of the smart work revolution.

Explore articles with tips and insights to know your about clinical matching

Contact us
Navigation
  • Home
  • About us
  • Clinical trials
  • Blog
  • Home
  • About us
  • Clinical trials
  • Blog
Address

L1N6Y1 / 26

Winston Crescent

Whitby, ON

Canada

Legal
  • Terms of use
  • Privacy Policy
  • Contact us
  • Terms of use
  • Privacy Policy
  • Contact us
Contact
+1 587-664-4986 info@horizonnt.ca
Get in touch
Horizon trial
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started